Avanir Pharma (AVNR) Cash Flow Statement

Click line-items for a historical chart and %

OPERATING ACTIVITIES:
Net loss	-50.44M
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1.4M
Share-based compensation expense	6.68M
Changes in operating assets and liabilities:
Trade receivables	-10.31M
Royalty receivables
Inventories	75K
Prepaid expenses and other assets	-1.78M
Accounts payable	372K
Accrued expenses and other liabilities
Accrued compensation and payroll taxes	2.22M
Deferred product revenues, net	0
Deferred royalty revenues	-1.29M
Net cash used in operating activities
INVESTING ACTIVITIES:
Purchase of investments in securities
Proceeds from sales and maturities of investments in securities
Purchase of property and equipment	-3.06M
Net cash used in investing activities
FINANCING ACTIVITIES:
Proceeds from issuances of common stock, net of commissions and offering costs	295.35M
Proceeds from exercise of stock options and warrants	3.32M
Collection of stock subscriptions receivable
Shares surrendered to pay for tax withholding
Net cash provided by financing activities
Net increase in cash and cash equivalents	216.61M
Cash and cash equivalents at beginning of period	55.26M
Cash and cash equivalents at end of period	271.87M
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Income taxes paid	3K
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Purchase of property and equipment in accounts payable and accrued expenses and other liabilities	561K

Entities mentioned with AVNR